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tion. Patients were divided into good responders (GR) or poor responders (PR) based
upon % change in LDL-C from baseline after initial statin dose.
Results: At baseline, PR had lower total cholesterol (TC) (227±35 vs 258±36 mg/
dl;p<0.001) and lower LDL-C (149±29 vs 173±28 mg/dl; p<0.001). Initial change in LDL-
C was -30.8±8.7% in GR vs. -8±7.2% in PR (p<0.01). Dose titration led to an additional
14.7±9.4% reduction in LDL-C in GR vs. only additional 7.7±11.6% in PR (p<0.001).
After dose titration, PR had less change from baseline in LDL-C (-15.7±14.6% vs -
45.5±12%; p<0.001). After dose titration, 18% of PR achieved LDL goal compared to
71% of GR (p<0.001). % LDL-C decrease after dose titration correlated with initial
response (r2=0.72).
Conclusions: Response to initial statin dose predicts response to dose titration. Dose
titration of statins is therefore not an effective strategy to reach aggressive LDL goals in
patients who have a poor initial LDL reduction. Other approaches such as combination
therapy need to be evaluated in this group of patients.
1084-172 Rosuvastatin Is Efficacious as Monotherapy in Patients 
With Combined Dyslipidemia
Fahim Abbasi, James W. Chu, Cindy Lamendola, Tracey McLaughlin, Valerie Cain, 
Howard G. Hutchinson, Gerald M. Reaven, Stanford University, Stanford, CA
Cardiovascular disease (CVD) risk is greater in patients with combined dyslipidemia
(CDL) than in those with isolated increases in fasting plasma triglyceride (TG) or low-
density lipoprotein (LDL) cholesterol (C) concentrations. Effective treatment (Rx) of CDL
has been confounded by: 1) concern of the increased risk of myopathy associated with
combined use of a “statin” and a fibric acid; and 2) neglecting the effect of Rx on post-
prandial (PP) lipemia. This study was initiated to test the hypothesis that the magnitude
of improvement in both fasting and PP lipid metabolism in rosuvastatin (RSV)-treated
subjects with CDL would obviate the need for combined drug Rx. Forty nondiabetic sub-
jects with CDL were randomly assigned to Rx with either RSV (40 mg/day) or gemfibrozil
(GEM, 1200 mg/day) for 3 months, and multiple aspects of fasting and PP carbohydrate
and lipid metabolism measured before and after Rx. The two groups did not differ in age,
sex distribution, or BMI. Mean±SE (mg/dL) fasting plasma LDL-C levels fell (P<0.001) fol-
lowing RSV-Rx (138±7 vs. 62±4), but did not change in GEM-treated subjects (126±5 vs.
131±5). Fasting TG levels fell (P<0.001), and to a similar degree in GEM-treated (284±17
vs. 166±23) and RSV-treated (324±19 vs. 211±18) subjects. RSV-treated subjects also
had significantly greater decreases in apo B-100, apo E, and the apo B-100/apo A-1 ratio
compared to those treated with GEM. Daylong glucose, insulin, and free fatty acid levels
did not change with Rx, whereas PP-TG levels fell to a similar degree in both groups
(P<0.01). Although the PP-remnant lipoprotein-C levels fell significantly with Rx in both
groups, the magnitude of the change was greater in the RSV-Rx group (P<0.05). Finally,
RSV-Rx resulted in significant (P<0.001) reductions in C-reactive protein (median change
-57.6%) compared to GEM-Rx (median change -9.1%). Conclusion: In addition to the
expected substantial decrease in LDL-C, the improvement in both fasting and PP con-
centrations of TG-rich lipoproteins in RSV-treated subjects was equal to or greater than
that seen with GEM-Rx. These results demonstrate that RSV provides effective mono-
therapy to decrease lipoprotein-related CVD risk factors in subjects with CDL.
1084-173 Analysis of the Renal Safety of Atorvastatin in a Broad 
Spectrum of Patients With Dyslipidemia
William Sasiela, Halit Silbershatz, Michael Szarek, Pfizer Inc, New York, NY
Background: This report summarizes the renal safety data from >9000 patients exposed
to atorvastatin for up to 2 years in completed clinical trials. These data are especially
important in the current climate which has seen increased scrutiny placed on all aspects
of the safety of chronic statin therapy.
Methods: Data were analyzed from 16,731 dyslipidemic patients (9976 male/6755
female; median age 61 yrs) enrolled in 44 clinical trials. The studies included 9416 atorv-
astatin-treated patients, 1789 placebo-treated patients and 5526 patients treated with
other statins (simvastatin [2771]; pravastatin [807]; lovastatin [968]; fluvastatin [744];
cerivastatin [236]). A broad spectrum of dyslipidemic patients with varying risks for car-
diovascular events were evaluated for up to 2 years. 
Results: Across the 44 studies analyzed, renal adverse events were rare in all 3 treat-
ment groups. Albuminuria was observed in 7 patients receiving atorvastatin (0.07%),
compared to 5 patients receiving other statins (0.09%) and 0 patients receiving placebo.
No case of albuminuria was considered to be treatment related. The rate of occurrence of
hematuria was also low in all treatment groups (atorvastatin, 44 patients [0.5%]; other
statins, 34 patients [0.6%]; placebo, 3 patients [0.2%]). Only in 1 atorvastatin and 1 pla-
cebo patient was hematuria considered to be possibly associated with study treatment.
In the subset of patients treated in placebo-controlled trials, there were no cases of albu-
minuria for either placebo or atorvastatin and hematuria was observed in 0.2% of
patients treated with placebo (3/1789) and in 0.3% of patients treated with atorvastatin
(8/2976). Overall, renal adverse events did not appear to be dose-related, and there were
no discontinuations considered related to renal adverse events.
Conclusion: Specific analysis of renal adverse events in 44 clinical trials demonstrates
that these occurred infrequently with atorvastatin and at similar rates to placebo. These
data provide further evidence to support the favorable clinical safety profile of atorvastatin
10 mg to 80 mg in a broad range of patients.
1084-174 Efficacy of Ezetimibe-10 mg/Day Coadministered With 
Multiple Doses of Simvastatin in Patients With Primary 
Hypercholesterolemia
Anne C. Goldberg, Rachel Capece, Aditi Sapre, Ji Liu, Yale Mitchel, Washington 
University, St. Louis, MO, Merck Research Laboratories, Rahway, NJ
Background: The cholesterol absorption inhibitor, ezetimibe (EZE), has a complemen-
tary mechanism of action to statins, which inhibit hepatic cholesterol synthesis. The pur-
pose of this study was to evaluate the LDL-C-lowering efficacy of EZE 10 mg/d
coadministered with simvastatin (SIM) 10, 20, 40, and 80 mg/d in hypercholesterolemic
patients (pts).
Methods: This was a 12 wk multicenter, double-blind, randomized, placebo (PBO)-con-
trolled study. After a 4-wk PBO/diet run-in, 887 pts with LDL-C 145 - 250 mg/dL and TG
<350 mg/dL were randomized to one of ten daily treatments: PBO; EZE 10 mg; SIM 10,
20, 40, or 80 mg; EZE 10 mg + SIM 10, 20, 40, or 80 mg.
Results: Results for LDL-C, non-high density lipoprotein cholesterol (non-HDL-C), trig-
lycerides (TG), and HDL-C by dose are summarized in the table. Pooled across the dose
ranges, EZE+SIM was more effective (p <0.001) than SIM in reducing LDL-C (-53.1% vs.
-38.3%), TG (-28.0% vs. -15.2%) and non-HDL-C (-48.5% vs. -34.1%), while HDL-C was
increased by 8% in both groups. A greater proportion of EZE+SIM pts reached the LDL-
C target of <100mg/dL (p <0.001): 82.4% (n=353) vs. 42.9% (n=345). Coadministration
of EZE+SIM was well tolerated and had an overall safety profile similar to that of SIM
monotherapy. However, there were more cases of consecutive >3 x upper limit of normal
elevations of aminotransferases in the EZE+SIM group vs. SIM group.
Conclusions: Overall, EZE+SIM was well tolerated and provided superior lipid-modify-
ing efficacy over SIM monotherapy.
1084-175 Changes in Coronary Plaque Color and Morphology by 
Lipid-Lowering Therapy With Atorvastatin: Serial 
Evaluation by Coronary Angioscopy
Masamichi Takano, Kyoichi Mizuno, Shigenobu Inami, Fumiyuki Ishibashi, Kentaro 
Okamatsu, Koji Seimiya, Takayoshi Ohba, Shinya Yokoyama, Shunta Sakai, Noritake 
Hata, Nippon Medical School, Chiba, Japan, Chiba-Hokusoh Hospital, Chiba, Japan
Background: The concept of coronary plaque stabilization by statin therapy has been
clarified. However, serial changes of coronary plaques by statin therapy in human have
not been examined in detail.
Methods: Thirty-one patients with coronary artery disease were devided into either the
comparison group (n=16) or the atorvastatin group (n=15). Before treatment and 12
months after, the color and complexity of 145 coronary plaques were determined accord-
ing to angioscopic findings. The yellow score of the plaque was defined as 0 (white), 1
(light yellow), 2 (yellow), or 3 (dark yellow), and its disrupted score was defined as 0
(smooth surface) or 1 (irregular surface) and as 0 (without thrombus) or 1 (with throm-
bus). In each patient, the mean yellow score and mean disrupted score were calculated.
Results: Mean low-density lipoprotein cholesterol (LDL-C) decreased by 45% in the ator-
vastatin group, whereas an increase of 9% was seen in the comparison group. The mean
yellow score decreased from 2.03 to 1.13 in the atorvastatin group, whereas it increased
from 1.67 to 1.99 in the comparison group. There was a good correlation between the
change in the mean yellow score and the change in LDL-C levels (r=0.81, p<0.0001).
The change in the mean yellow score and mean disrupted score differed significantly
between the two groups (p=0.002 and p=0.03, respectively).
Conclusions: This study indicated that lipid-lowering therapy changes plaque color and
morphology and should then lead to coronary plaque stabilization.
1084-176 Efficacy of Ezetimibe Coadminstered With Simvastatin 
Versus Atorvastatin in Patients With 
Hypercholesterolemia
Christie M. Ballantyne, Michael A. Blazing, Thomas R. King, William E. Brady, Joanne 
Palmisano, Merck & Company, Inc., West Point, PA
Background: This study was designed to evaluate the efficacy and safety of ezetimibe
coadministered with simvastatin (EZ/S) vs atorvastatin (A) in adults with hypercholester-
olemia.
Methods: After a four-week diet/placebo run-in period, eligible patients were randomized
1:1:1 to 3 treatment groups, each for four 6-week periods: (1) A10 mg titrated to A20 mg,
A40 mg, and A80 mg through Periods 1-4; (2) EZ/S 10 mg (10/10) titrated to EZ/S 20 mg
LDL-C response in GR vs. PR
Good Responders 
(n=38)
Poor Responders 
(n=38)
Change in LDL-C after initial 
dose
-30.8±8.7% -8.07.2%± p<0.001
Change in LDL-C after dose 
titration (from baseline)
-45.5±12% -15.7±14.6% p<0.001
% at  ATP III Goal 71% 18% p<0.001
Mean Percent Change from Baseline
Lipid 
Parameter
SIM 
10mg 
(n=79)
EZE/SIM 
10mg/10mg 
(n=87)
SIM 
20mg 
(n=89)
EZE/SIM 
10mg/20mg 
(n=86)
SIM 
40mg 
(n=90)
EZE/SIM 
10mg/40mg 
(n=89)
SIM 
80mg 
(n=87)
EZE/SIM 
10mg/80mg 
(n=91)
LDL
-C
-
31.
3
-
46.
2
-
34.
9
-
50.
5
-
41.
5
-
54.
9
-
45.
6
-
60.8
Total C -20.7 -31.5 -24.1 -36.5 -28.7 -39.5 -31.7 -43.0
non-
HDL-C
-26.8 -41.3 -31.2 -47.1 -37.0 -50.9 -41.4 -54.8
TG 
(median)
-4.5 -20.5 -13.6 -30.7 -18.6 -32.0 -25.7 -27.8
HDL-C 4.9 9.5 6.3 8.0 8.3 9.1 11.0 6.3
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(10/20), EZ/S 40 mg (10/40), and EZ/S 80 mg (10/80) through Periods 1-4; and (3) EZ/S
20 mg titrated to EZ/S 40 mg (for Periods 2 and 3), then EZ/S 80 mg for Period 4. Primary
endpoint was % change from baseline in LDL-C after the initial 6-week period. Second-
ary endpoints included % change from baseline in LDL-C to ends of Periods 2, 3, and 4;
and HDL-C to ends of Periods 1, 2, 3, and 4. Safety measurements were clinical and lab-
oratory adverse events including ALT or AST _3x upper limit of normal (ULN), CK _10x
ULN.
Results: Baseline LDL-C and HDL-C levels were comparable between treatment groups.
At the end of Period 1, mean LDL-C reduction and mean HDL-C increase were signifi-
cantly (p_0.01) greater for the EZ/S 10 mg and EZ/S 20 mg groups compared with the
A10 mg group (see Table). At the end of Period 4, comparing maximum doses, EZ/S 80
mg was superior to A80 mg in LDL-C reduction (–59.4 vs –52.5) and HDL-C increase
(12.3 vs 6.5). 
Conclusion: Greater LDL-C reduction and HDL-C increase can be attained by treating 
with EZ/S compared with atorvastatin. Treatments with EZ/S and A were well-tolerated.
1084-178 Trends in Use of Statins in Older Patients With Acute 
Myocardial Infarction
JoAnne M. Foody, Deron H. Galusha, Frederick A. Masoudi, Saif S. Rathore, Edward P. 
Havranek, Harlan M. Krumholz, Yale University School of Medicine, New Haven, CT
Background: Treatment with HMG CoA Reductase Inhibitors (statins) decreases cardio-
vascular events and mortality in patients with coronary artery disease (CAD). Little is
known regarding trends in the use of statins in a population-based sample of older
patients surviving acute myocardial infarction (AMI).
Methods and Results: In two national cohorts of 31,399 and 31,759 older patients hospi-
talized between 1998-9 and 2000-1 with confirmed AMI, we identified patients who sur-
vived to discharge. We assessed change in rates of use of statins at discharge in ‘ideal
candidates’ without contraindications to statins. Overall, 27.5% and 46.2% of patients
were discharged in 1998-9 and 2000-1, respectively. Of those patients with an LDL-c
greater than the guideline-based threshold of 130 mg/dL, 55% received lipid-lowering
therapy in 1998-9 compared to 71% in 2000-1. In general, women and the elderly were
consistently less likely to receive statins on discharge.
Conclusions: In a national sample of older AMI survivors, significant increases in dis-
charge prescription of statins occurred irrespective of patient age, sex, race and LDL
cholesterol. Despite these increases, a significant proportion of older patients do not
receive guideline-based lipid management.
1084-179 Ezetimibe/SimvastatinTherapy Is More Effective Than 
Simvastatin Alone at Reducing Remnant-Like Particle 
Cholesterol
Harold E. Bays, Leiv Ose, Neil Fraser, Katherine L. Quinto, Robert Reyes, Aditi Sapre, 
Diane Tribble, Stephen R. Donahue, Louisville Metabolic and Atherosclerosis Research 
Center, Louisville, KY, Merck Research Laboratories, Rahway, NJ
Background: Levels of remnant lipoproteins are independent predictors of future coro-
nary events in patients with coronary artery disease. We evaluated the effects of
ezetimibe/simvastatin (EZE/SIM) combination therapy versus SIM alone on remnant-like
particle cholesterol (RLP-C) in hypercholesterolemic patients.
Methods: After a 6- to 8-wk washout and a 4-wk diet/placebo run-in, 1528 patients with
LDL-C 145 - 250 mg/dL and triglycerides <350 mg/dL, were randomized to one of the fol-
lowing daily treatments for 12 wks: EZE/SIM tablet (10/10, 10/20, 10/40, or 10/80 mg/
mg); SIM alone (10, 20, 40, or 80 mg); EZE 10 mg; or placebo. The primary endpoint was
% change from baseline in LDL-C for pooled EZE/SIM vs pooled SIM alone. RLP-C lev-
els were measured using an immune separation assay.
Results: EZE/SIM produced significantly greater reductions in RLP-C than did SIM alone
(table). For each SIM dose comparison, RLP-C was reduced more by the EZE/SIM com-
bination (range: -31.8% to -47.4%) than by the corresponding dose of SIM alone (range:
-22.5% to -37.5%; p<0.001 for all comparisons). The effects of EZE/SIM on RLP-C were
consistent with the effects on LDL-C (-53.1% vs -39.0%; p<0.001); apolipoprotein B (-
42.4% vs -31.6%; p<0.001); non-HDL-C (-48.7% vs -35.9%; p<0.001); and triglyceride (-
24.3% vs -20.8%; p<0.001).
Conclusion: EZE/SIM in a single tablet (10/10 to 10/80 mg/mg) is more effective than
the corresponding dose of SIM alone in reducing plasma levels of potentially atherogenic
remnant lipoproteins.
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1085-165 Aliskiren, a Novel, Orally Effective Nonpeptide Renin 
Inhibitor, Lowers Blood Pressure After Once-Daily 
Dosing in Marmosets, Rats and Humans
Jeanette M. Wood, Randy L. Webb, Frederic Cumin, Christian R. Schnell, Martin P. 
Bedigian, Novartis Institute for Biomedical Research, Basel, Switzerland, Novartis, East 
Hanover, NJ
Background: Renin inhibitors (RIs) provide an attractive new therapeutic approach to the
treatment of hypertension, as they block the first and rate-limiting step of the renin-angio-
tensin system (RAS). The present study investigates the in vivo effects of aliskiren, the
first of a new class of non-peptide RIs.
Methods: Aliskiren was administered orally to normotensive, sodium-depleted marmo-
sets and to hypertensive (mean systolic BP > 140 mmHg) human patients, and subcuta-
neously to spontaneous hypertensive rats (SHR). In animal studies, changes in mean
arterial pressure (MAP; mean±s.e.mean) and heart rate were measured continuously by
telemetry; 24 h ambulatory BP measurement was used in humans. Plasma renin activity
was measured by antibody trapping assay.
Table. Summary of Endpoints
LS-Mean Percent Change 
from Baseline in:
Period Group Treatment n available 
for analysis†
LDL-C HDL-C
1 1 Atorvastatin 10 mg 250 –37.2 5.1
2 Ezetimibe/Simvastatin 
10 mg
252 –46.1‡ 8.0‡
3 Ezetimibe/Simvastatin 
20 mg
253 –50.3‡ 9.5‡
2 1 Atorvastatin 20 mg 235 –44.3 6.9
2 Ezetimibe/Simvastatin 
20 mg
239 –50.2‡ 9.0
3 Ezetimibe/Simvastatin 
40 mg
243 –54.3‡ 12.4‡
3 1 Atorvastatin 40 mg 228 –49.1 7.8
2&3* Ezetimibe/Simvastatin 
40 mg
466 –55.6‡ 11.4‡
4 1 Atorvastatin 80 mg 223 –52.5 6.5
2&3* Ezetimibe/Simvastatin 
80 mg
441 –59.4‡ 12.3‡
LS means and p-values are from analysis of variance model with terms for treatment 
and baseline LDL-C strata. †Baseline values for LDL-C (mg/dL) were: (Group 1, 180.6; 
Group 2, 180.0; Group 3, 179.2), for HDL-C: (Group 1, 46.9; Group 2, 46.6; Group 3, 
46.8). ‡p_0.01 for difference with Atorvastatin in the specified period.
*Treatment Groups 2 and 3 combined in Periods 3 and 4.
Rates of Statin Use in Older AMI Survivors
1998-9
N =14,808
%
2000-1
N =14,606
%
Overall Use 27.5 46.2
Age >/= 75 years * 21.6 40.1
LDL <100 mg/dL 28.8 47.4
LDL 100-129 mg/dL 34.7 56.2
LDL >/=130 mg/dL 55.0 71.3
* in ideal patients with LDL-c ³ 130 mg/dL
Effect of Treatment on RLP-C
Pbo
(N=141)
EZE 10 mg
(N=144)
Pooled
SIM
(N=597)
Pooled
EZE/SIM
(N=570)
Baseline RLP-C (mg/dL) 13.3 14.0 14.0 14.0
% Change from baseline 5.4 -15.6^ -29.31^ -40.6*^
*p<0.001 versus Pooled SIM; ^p<0.001 versus Pbo
RLP-C: remnant-like particle cholesterol; Pbo: placebo; EZE: ezetimibe; SIM: 
simvastatin
